← Back to headlines
H.C. Wainwright Reiterates Buy on Beam Therapeutics After FDA Expedited Approval
H.C. Wainwright has reiterated its 'Buy' rating on Beam Therapeutics (BEAM) following the FDA's expedited approval of BEAM-302.
15 Feb, 13:41 — 15 Feb, 13:41
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Investment Outlook: Dividend Aristocrats Poised for 2026 Rebound
17m ago
Stock Market Today, Feb. 20: CoreWeave Falls After Blue Owl Data Center Financing Failure Raises Funding Concerns
57m ago
Why CoreWeave Was Plunging To End the Week Today
57m ago
Costco Price Target Raised by Evercore ISI and Citi After Q2 Beat
57m ago